The cholinergic system and treatment response in subtypes of Alzheimer’s disease
Authors:
- Alejandra MachadoAMAlejandra Machado
- Daniel FerreiraDFDaniel Ferreira
- Michel J. GrotheMGMichel J. Grothe
- Helga EyjolfsdottirHEHelga Eyjolfsdottir
- Per M. AlmqvistPAPer M. Almqvist
- Lena CavallinLCLena Cavallin
- Göran LindGLGöran Lind
- Bengt LinderothBLBengt Linderoth
- Åke SeigerÅSÅke Seiger
- Stefan TeipelSTStefan Teipel
- Lars U. WahlbergLWLars U. Wahlberg
- Lars-Olof WahlundLWLars-Olof Wahlund
Preprint
Abstract
BACKGROUND: The heterogeneity within Alzheimer’s disease (AD) seriously challenges the development of disease modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subtypes of AD, and explored the relevance of subtype stratification in a clinical trial on encapsulated cell biodelivery (ECB) of nerve growth factor (NGF) to the basal forebrain. METHODS: Structural MRI data was collected for 90 amyloid-positive patients and 69 amyloid-negative healthy controls at baseline, 6-, 12-, and 24-month follow-up. The effect of the NGF treatment was investigated in 10 biopsy verified AD patients with structural MRI data at baseline and at 6- or 12-months follow-up. Patients were classified as typical, limbic-predominant, hippocampal-sparing, or minimal atrophy AD, using a validated visual assessment method. Volumetric analyses were performed using a region-of-interest approach. RESULTS: All AD subtypes showed reduced basal forebrain volume as compared with controls. Limbic-predominant subtype showed fastest basal forebrain atrophy rate, whereas minimal atrophy subtype did not show significant volume decline over time. Atrophy rates of hippocampus and precuneus also differed across subtypes. The NGF treatment seemed to slow the rate of atrophy in precuneus and hippocampus, particularly in the hippocampal-sparing AD subtype. CONCLUSIONS: The cholinergic system is differentially affected in distinct atrophy subtypes of AD, possibly contributing to their differential response to cholinergic treatment. Our findings suggest that future clinical trials should target specific subtypes of AD, or at least report treatment effects stratifying by subtype. Trial registration: ClinicalTrials.gov identifier: NCT01163825 . Registered 14 July 2010 - https://clinicaltrials.gov/ct2/show/NCT01163825Keywords
All Related Versions
- Published version: Alzheimer's Research & Therapy, 12 (1), 1.
This publication has 52 references indexed in Scilit:
- The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkersNeurobiology of Aging, 2018
- Heterogeneous patterns of brain atrophy in Alzheimer's diseaseNeurobiology of Aging, 2018
- Alzheimer's disease drug development pipeline: 2018Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2018
- Distinct subtypes of Alzheimer’s disease based on patterns of brain atrophy: longitudinal trajectories and clinical applicationsScientific Reports, 2017
- Heterogeneity of neuroanatomical patterns in prodromal Alzheimer’s disease: links to cognition, progression and biomarkersBrain, 2016
- Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery deviceAlzheimer's Research & Therapy, 2016
- Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer’s DiseasePLOS ONE, 2015
- Deep Brain Stimulation of the Nucleus Basalis of Meynert in Early Stage of Alzheimer's DementiaBrain Stimulation, 2015
- Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control studyThe Lancet Neurology, 2012
- Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective studyThe Lancet Neurology, 2011